Serum Midkine Levels in Systemic Lupus Erythematosus

  • Blondina Marpaung Division of Rheumatology, Faculty of Medicine Universitas of Sumatera Utara, Medan
  • Andi Raga Ginting Division of Rheumatology, Faculty of Medicine Universitas of Sumatera Utara, Medan
  • OK Moehad Sjah Division of Rheumatology, Faculty of Medicine Universitas of Sumatera Utara, Medan
Keywords: Midkine, Systemic Lupus Erythematosus


BACKGROUND: Midkine (MK) induces inflammation and could inhibit inducible regulatory T cell differentiation. These reports suggest that MK may play a role in the pathogenesis of autoimmune disease including SLE, but data about MK in SLE patients was still limited, and the role of Midkine in SLE is largely unknown.

AIM: The purpose of this study was to compare serum level MK in SLE patients and control, also analysed the relationship between the serum MK level and disease activity in SLE.

METHODS: This cross-sectional study was conducted in Adam Malik Hospital from January-June 2017. Diagnosis of SLE was established according to the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, and disease activity was assessed using the Mexican Systemic lupus erythematosus disease activity index (MEX-SLEDAI). Subjects with evidence of malignancy and systemic disease (pulmonary, kidney, liver, metabolic disorder, etc.) were excluded. Data analysis was performed using SPSS 22nd version. P < 0.05 was considered statistically significant.

RESULTS: There were 90 subjects and divided into 2 groups: SLE patients group (n=40) and healthy control groups (n = 50). Midkine levels were increased in the serum of SLE patients compared by health control. There was a significant difference in the median serum Midkine levels between SLE patients and healthy control (P < 0.001). Elevated Midkine serum levels were a significant difference between active disease and remission (P = 0.018).

CONCLUSION: Elevated Midkine serum level could be a marker of SLE disease activity and have a role in the pathogenesis of SLE.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Buyon JP. Systemic Lupus Erythematosus. In: Klippel JH, Stone JH, Crofford LeJ, White PH, eds. Primer on the Rheumatic Diseases. Springer, 2008:303-338.

Tahernia L, Namazi S, Rezaei N and Ziaee V. Cytokines in systemic lupus eryhtematosus: their role in pathogenesis of disease and possible therapeutic opportunities. Rheum Res. 2017; 2(1):1-9.

Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13:228. PMid:21745419 PMCid:PMC3239336

Ibusuki M, Fujimori H, Yamamoto Y, Ota K, Ueda M, Shinriki S, et al. Midkine in plasma as a novel breast cancer marker. Cancer Sci. 2009; 100(9):1735–1739. PMid:19538527

Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 2002; 132: 359-371. PMid:12204104

Hung YJ, Lin ZH, Cheng TI, Liang CT, Kuo TM and Kao KJ. Serum Midkine as a Prognostic Biomarker for Patients With Hepatocellular Carcinoma. Am J Clin Pathol. 2011; 136:594-603. PMid:21917682

Weckbach LT, Muramatsu T, Walzog B. Midkine in inflammation. Sci World J. 2011; 11:2491–2505. PMid:22235180 PMCid:PMC3253530

Wang J, Takeuchi H, Sonobe Y, Jin S, Mizuno T, Miyakawa S, et al. Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A. 2008; 105: 3915-3920. PMid:18319343 PMCid:PMC2268842

Sonobe Y, Li H, Jin S, Kishida S, Kadomatsu K, Takeuchi H, et al. Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells. J Immunol. 2012; 188:2602–2611. PMid:22323540

Shindo E, Nanki T, Kusunoki N, Shikano K, Kawazoe M, Sato H, et al. The growth factor midkine may play a pathophysiological role in rheumatoid arthritis. Mod Rheumatol. 2016; 1:1–6

Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677. PMid:22553077 PMCid:PMC3409311

Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology. 2004; 43(12):1536-40. PMid:15342925

Scheinecker C, Bonelli M and Smolen JS. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun. 2010; 35: 269-275. PMid:20638240

Ohi K and Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015; 45(2):344-355. PMid:25378177

Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012; 18: 871-882. PMid:22674006 PMCid:PMC3607103

Masuda T, Maeda K, Sato W, et al. Growth factor midkine promotes nuclear factor of activated T cells-regulated T-cell- activation and Th1 cell differentiation in lupus nephritis. Am J Pathol. 2017; 184(4):740-751. PMid:28183532

Wu GC, Yuan H, Pan HF, Ye DQ. Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus. Oncotarget. 2017; 8(25): 40181-40189. PMid:27903979 PMCid:PMC5522313

Shaygannejad V, Montazeri S, Jamshidian A, et al. Correlation of midkine serum level with pro-and anti-inflamatory cytokines in multiple sclerosis. Iran J Immunol. 2014; 11:134–138. PMid:24975970

Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Clinical relevance of circulating midkine in ulcerative colitis. Clin Chem Lab Med. 2009; 47:1085–1090. PMid:19728850

Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Circulating midkine in Crohn's disease: clinical implications. Inflamm Bowel Dis. 2010; 16:208–215. PMid:19572374

How to Cite
Marpaung B, Ginting AR, Sjah OM. Serum Midkine Levels in Systemic Lupus Erythematosus. Open Access Maced J Med Sci [Internet]. 2018Aug.14 [cited 2020Nov.26];6(8):1323-7. Available from:
A - Basic Science